Neurocrine reports Q4 adjusted EPS $1.69, consensus $1.93
Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...
American Association of Individual Investors6h
Which Is a Better Investment, Biogen Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Investor's Business Daily on MSN4h
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Neurocrine sees FY25 Ingrezza net product sales $2.5B-$2.6B
FY25 revenue consensus $2.79B.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Tokio Marine Asset Management Co. Ltd.
Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...
FierceBiotech9d
Takeda regains home rights to phase 3-stage depression drug from Neurocrine
Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...
Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now
We recently compiled a list of the 12 Best Low Risk High Growth Stocks to Invest In. In this article, we are going to take a ...
Neurocrine price target raised to $184 from $182 at BofA
BofA raised the firm’s price target on Neurocrine (NBIX) to $184 from $182 and keeps a Buy rating on the shares. The firm, which highlights ...